Xiong-Zhi Wu1, Feng Ma, Xue-Lin Wang. 1. Department of Zhong-Shan-Men In-patient, Cancer Institute and Hospital, Tianjin Medical University, Jintang Road, Hedong District, Tianjin, China. ilwxz@163.com
Abstract
AIM: To investigate the serological diagnostic factors for liver metastasis in patients with colorectal cancer. METHODS: One hundred and six adult in-patients with colorectal cancer were studied and divided into patients with liver metastasis (n = 56) and patients without liver metastasis (n = 50). Serum levels of tumor and biochemical markers for liver were measured at the time of diagnosis. RESULTS: The mean survival time was 55.9 mo, 36.8 mo and 68.3 mo for the overall patients, patients with liver metastasis and patients without liver metastasis, respectively. Lactate dehydrogenase (LDH) level was significantly correlated with the survival time of colorectal cancer patients. The levels of alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase (GGT), LDH and carcinoembryonic antigen (CEA) were significantly higher in patients with liver metastasis than in those without liver metastasis. Patients with lymph node metastasis had a higher risk of liver metastasis than those without lymph node metastasis. The cut points of LDH, GGT and CEA for screening liver metastasis were 180 U/L, 30 U/L and 5.0 microg/L, respectively. The sensitivity was 64.3%, 69.6% and 70.4%, and the specificity was 64.0%, 60.0% and 52.4%, respectively. The sensitivity of parallel test was 85.2% for LDH and CEA, and 92.6% for GGT and CEA, respectively. The specificity of serial test was 85.7% for LDH (or GGT) and CEA. CONCLUSION: Early diagnosis of liver metastasis is of great significance. The sensitivity and specificity of combined tumor and biochemical markers are rather good in screening colorectal liver metastasis.
AIM: To investigate the serological diagnostic factors for liver metastasis in patients with colorectal cancer. METHODS: One hundred and six adult in-patients with colorectal cancer were studied and divided into patients with liver metastasis (n = 56) and patients without liver metastasis (n = 50). Serum levels of tumor and biochemical markers for liver were measured at the time of diagnosis. RESULTS: The mean survival time was 55.9 mo, 36.8 mo and 68.3 mo for the overall patients, patients with liver metastasis and patients without liver metastasis, respectively. Lactate dehydrogenase (LDH) level was significantly correlated with the survival time of colorectal cancerpatients. The levels of alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase (GGT), LDH and carcinoembryonic antigen (CEA) were significantly higher in patients with liver metastasis than in those without liver metastasis. Patients with lymph node metastasis had a higher risk of liver metastasis than those without lymph node metastasis. The cut points of LDH, GGT and CEA for screening liver metastasis were 180 U/L, 30 U/L and 5.0 microg/L, respectively. The sensitivity was 64.3%, 69.6% and 70.4%, and the specificity was 64.0%, 60.0% and 52.4%, respectively. The sensitivity of parallel test was 85.2% for LDH and CEA, and 92.6% for GGT and CEA, respectively. The specificity of serial test was 85.7% for LDH (or GGT) and CEA. CONCLUSION: Early diagnosis of liver metastasis is of great significance. The sensitivity and specificity of combined tumor and biochemical markers are rather good in screening colorectal liver metastasis.
Authors: S Bipat; M S van Leeuwen; J N M Ijzermans; E F I Comans; A S Th Planting; P M M Bossuyt; J-W Greve; J Stoker Journal: Neth J Med Date: 2007-01 Impact factor: 1.422
Authors: M J Duffy; A van Dalen; C Haglund; L Hansson; R Klapdor; R Lamerz; O Nilsson; C Sturgeon; O Topolcan Journal: Eur J Cancer Date: 2003-04 Impact factor: 9.162
Authors: Nick A van Huizen; Robert R J Coebergh van den Braak; Michael Doukas; Lennard J M Dekker; Jan N M IJzermans; Theo M Luider Journal: J Biol Chem Date: 2018-11-08 Impact factor: 5.157
Authors: Johanna Winter; Max M Lenders; Maximilian Gassenmaier; Andrea Forschner; Ulrike Leiter; Benjamin Weide; Mette-Triin Purde; Lukas Flatz; Antonio Cozzio; Martin Röcken; Claus Garbe; Thomas K Eigentler; Nikolaus B Wagner Journal: Cancer Immunol Immunother Date: 2020-10-28 Impact factor: 6.968
Authors: J Feliu; I Díez de Corcuera; J L Manzano; M Valladares-Ayerbes; J Alcaide; T García García; R Vera; J Sastre Journal: Clin Transl Oncol Date: 2016-10-07 Impact factor: 3.405
Authors: Roman O Kowalchuk; Michael R Waters; K Martin Richardson; Kelly M Spencer; James M Larner; C R Kersh Journal: Rep Pract Oncol Radiother Date: 2020-10-02